Abstract
The facile synthesis of a key intermediate for the total synthesis of the antiangiogenic compound fumagillin, its semisynthetic analogue TNP-470, and ovalicin is described. The methodology employs a Diels-Alder strategy and a zinc-mediated ring-opening reaction to realize the cyclohexane backbone.
Key words
angiogenesis inhibitors - Diels-Alder reaction -
syn reduction - dihydroxylation - HIV
References
1a Hanahan D.
Folkman J.
Cell
1996,
86:
353
1b Folkman J.
Nat. Med.
1995,
1:
27
1c Folkman J.
Klagsbrun M.
Science
1987,
235:
442
1d McCowen MC.
Callender ME.
Lawlis JF.
Science
1951,
113:
202
2a Powell D.
Skotnicki J.
Upeslacis J.
Annu. Rep. Med. Chem.
1997,
32:
161
2b Giannis A.
Rubsam F.
Angew. Chem., Int. Ed. Engl.
1997,
36:
588
2c Auerbach W.
Auerbach R.
Pharmacol. Ther.
1994,
63:
265
2d Folkman J.
N. Engl. J. Med.
1971,
285:
1182
3a Killough JH.
Magill GB.
Smith RC.
Science
1952,
115:
71
3b Katznelson H.
Jamieson CA.
Science
1952,
115:
70
3c See also ref. 1d.
3d Eble TE.
Hanson FR.
Antibiot. Chemother. (Washington, D.C.)
1951,
1:
54
4a Asami Y.
Kakeya H.
Onose R.
Chang Y.-H.
Toi M.
Osada H.
Tetrahedron
2004,
60:
7085
4b Yamaguchi J.
Toyoshima M.
Shoji M.
Kakeya H.
Osada H.
Hayashi Y.
Angew. Chem. Int. Ed.
2006,
45:
789
5a O’Reilly MS.
Boehm T.
Shing Y.
Fukai N.
Vasios G.
Lane WS.
Flynn E.
Birkhead JR.
Olsen BR.
Folkman J.
Cell
1997,
88:
277
5b Oh SP.
Warman ML.
Seldin MF.
Cheng SD.
Knoll JHM.
Timmons S.
Olsen BR.
Genomics
1994,
19:
494
6a O’Reilly MS.
Holmgren L.
Shing Y.
Chen C.
Rosenthal RA.
Moses M.
Lane WS.
Cao Y.
Sage EH.
Folkman J.
Cell
1994,
79:
315
6b Gately S.
Twardowski P.
Stack MS.
Patrick M.
Boggio L.
Cundiff DL.
Schnaper HW.
Madison L.
Volpert O.
Bouck N.
Enghild J.
Kwaan HC.
Soff GA.
Cancer Res.
1996,
56:
4887
7a Sigg HP.
Weber HP.
Helv. Chim. Acta
1968,
51:
1395
7b Sassa T.
Kaise H.
Munata K.
Agric. Biol. Chem.
1970,
34:
649
7c Corey EJ.
Dittami JP.
J. Am. Chem. Soc.
1985,
107:
256
7d Tiefenbacher K.
Arion VB.
Mulzer J.
Angew. Chem. Int. Ed.
2007,
46:
1
8a Ingber D.
Fujita T.
Kishimoto S.
Sudo K.
Kanamaru T.
Brem H.
Folkman J.
Nature
1990,
348:
555
8b Figg WD.
Kruger EA.
Expert Opin. Invest. Drugs
2000,
9:
1383
8c Kwon J.
Jeong H.
Kang K.
Hang Y.
Bae K.
Choi J.
Lee U.
Son K.
Kown B.
J. Antibiot.
2000,
53:
799
9a See also ref. 3b.
9b See also ref. 3a.
9c Zhang P.
Nicholson DE.
Bujnicki JM.
Su X.
Brendle JJ.
Ferdig M.
Kyle DE.
Milhous WK.
Chiang PK.
J. Biomed. Sci.
2002,
9:
34
10a Molina JM, and Derouin F. inventors; PCT Int. Appl. WO 9630010.
; Chem. Abstr. 1996 , 125 , 309073
10b Coyle C.
Kent M.
Tanowitz HB.
Wittner M.
Weiss LM.
J. Infect. Dis.
1998,
177:
515
10c Molina JM.
Goguel J.
Sarfati C.
Michiels J.-F.
Desportes-Livage I.
Balkan S.
Chastang C.
Cotte L.
Maslo C.
Struxiano A.
Derouin F.
Decazes J.-M.
AIDS
2000,
14:
1341
11 Watanabe N.
Nishihara Y.
Yamaguchi T.
Koito A.
Miyoshi H.
Kakeya H.
Osada H.
FEBS Lett.
2006,
580:
2598
12 Corey EJ.
Snider BB.
J. Am. Chem. Soc.
1972,
94:
2549
13a Camara F.
Angarita J.
Mootoo DR.
J. Org. Chem.
2005,
70:
6870
13b Ciampini M.
Perlmutter P.
Watson K.
Tetrahedron: Asymmetry
2007,
18:
243
13c Bedel O.
Haudrechy A.
Pouilhes A.
Langlois Y.
Pure Appl. Chem.
2005,
77:
1139
13d Manitschek R.
Huwe A.
Giannis A.
Org. Biomol. Chem.
2005,
3:
2150
13e Vosburg DA.
Weiler S.
Sorensen E.
Chirality
2003,
15:
156
13f Picoul W.
Bedel O.
Haudrechy A.
Langlois Y.
Pure Appl. Chem.
2003,
75:
235
13g Fardis M.
Pyun HJ.
Tario J.
Jin HL.
Kim CU.
Ruckman J.
Lin Y.
Green L.
Hicke B.
Bioorg. Med. Chem.
2003,
11:
5051
13h Picoul W.
Urchequi R.
Haudrechy A.
Langlois Y.
Tetrahedron Lett.
1999,
40:
4797
13i Taber DF.
Christos TE.
Rheingold AL.
Guzei IA.
J. Am. Chem. Soc.
1999,
121:
5589
13j Hutchings M.
Moffat D.
Simpkins NS.
Synlett
2001,
661
13k Kim D.
Ahn SK.
Bae H.
Choi WJ.
Kim HS.
Tetrahedron Lett.
1997,
38:
4437
13l Vosburg DA.
Weiler S.
Sorensen EJ.
Angew. Chem. Int. Ed.
1999,
38:
971
13m Bedel O.
Haudrechy A.
Langlois Y.
Eur. J. Org. Chem.
2004,
3813
13n Boiteau J.-G.
Van de Weghe P.
Eustache J.
Org. Lett.
2001,
3:
2737
14a Yadav JS.
Sreedhar P.
Bhunia DC.
Srihari P.
Synlett
2007,
992
14b Yadav JS.
Chetia L.
Org. Lett.
2007,
9:
4587
14c Yadav JS.
Pratap TV.
Rajender V.
J. Org. Chem.
2007,
72:
5882
14d Srihari P.
Prem Kumar B.
Subbarayudu K.
Yadav JS.
Tetrahedron Lett.
2007,
48:
6977
14e Yadav JS.
Prathap I.
Tadi BP.
Tetrahedron Lett.
2006,
47:
3773
14f Yadav JS.
Srinivas R.
Sathaiah K.
Tetrahedron Lett.
2006,
47:
1603
14g Yadav JS.
Raju AK.
Rao PP.
Rajaiah G.
Tetrahedron: Asymmetry
2005,
16:
3283
14h Yadav JS.
Prakash SJ.
Gangadhar Y.
Tetrahedron: Asymmetry
2005,
16:
2722
14i Yadav JS.
Reddy MS.
Prasad AR.
Tetrahedron Lett.
2005,
46:
2133
15 Leroy J.
Synth. Commun.
1992,
22:
567
16 Nelson WL.
Allen DR.
Heterocycl. Chem.
1972,
9:
561
17 Leroy J.
Tetrahedron Lett.
1992,
33:
2969
18 Initially, we isolated the double-bond-reduced product with the PMB group intact and then proceeded with PMB deprotection using DDQ in CH2 Cl2 /H2 O. However, a prolonged reaction time with Pd/C also resulted in the saturated PMB-deprotected product.
19a Bernet B.
Vasella A.
Helv. Chim. Acta
1979,
62:
1990
19b Ferrier RJ.
Furneaux RH.
Prasit P.
Tyler PC.
Brown KL.
Gainsford GJ.
Diehl W.
J. Chem. Soc., Perkin Trans. 1
1983,
1621
19c Ferrier RJ.
Prasit P.
J. Chem. Soc., Perkin Trans. 1
1983,
1645
19d Ferrier RJ.
Schmidt P.
Tyler PC.
J. Chem. Soc., Perkin Trans. 1
1985,
301
19e Nicolaou KC.
Duggan ME.
Ladduwahetty T.
Tetrahedron Lett.
1984,
25:
2069
19f Yadav JS.
Reddy BVS.
Srinivasa Reddy K.
Tetrahedron
2003,
59:
5333
19g See also ref. 14a.
20 The reaction conditions employed for the attempted protection of the alcohol were (a) TBDPSCl, 1H -imidazole, CH2 Cl2 ; (b) MOMCl, DIPEA, CH2 Cl2 ; (c) BzCl, py, CH2 Cl2 , and those employed for the attempted ketal deprotection were (a) PTSA (cat.), acetone-H2 O; (b) CSA, acetone-H2 O; (c) PPTS, acetone-H2 O; (d) TMSOTf, CH2 Cl2 .
21 Mazitschek R.
Huwe A.
Giannis A.
Org. Biomol. Chem.
2995,
3:
2150
22 syn reduction was achieved by following a known protocol used for the stereoselective reduction of β-hydroxy ketone, see: Narasaka K.
Pai F.-C.
Tetrahedron
1984,
40:
2233
